$113 Million is the total value of Virtus ETF Advisers LLC's 261 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HTHT | Exit | CHINA LODGING GROUP LTDsponsored adr | $0 | – | -69 | -100.0% | -0.01% | – |
| LBTYA | Exit | LIBERTY GLOBAL PLC | $0 | – | -316 | -100.0% | -0.01% | – |
| XRX | Exit | XEROX CORP | $0 | – | -355 | -100.0% | -0.01% | – |
| FCX | Exit | FREEPORT-MCMORAN INCcl b | $0 | – | -694 | -100.0% | -0.01% | – |
| PVH | Exit | PVH CORP | $0 | – | -81 | -100.0% | -0.01% | – |
| WMT | Exit | WAL-MART STORES INC | $0 | – | -144 | -100.0% | -0.01% | – |
| LNG | Exit | CHENIERE ENERGY INC | $0 | – | -244 | -100.0% | -0.01% | – |
| BKR | Exit | BAKER HUGHES A GE COcl a | $0 | – | -465 | -100.0% | -0.01% | – |
| DPZ | Exit | DOMINOS PIZZA INC | $0 | – | -56 | -100.0% | -0.01% | – |
| F | Exit | FORD MTR CO DEL | $0 | – | -1,216 | -100.0% | -0.01% | – |
| RF | Exit | REGIONS FINL CORP NEW | $0 | – | -841 | -100.0% | -0.01% | – |
| C | Exit | CITIGROUP INC | $0 | – | -242 | -100.0% | -0.01% | – |
| SCHW | Exit | SCHWAB CHARLES CORP NEW | $0 | – | -532 | -100.0% | -0.02% | – |
| AVGO | Exit | BROADCOM LTD | $0 | – | -163 | -100.0% | -0.03% | – |
| TTPH | Exit | TETRAPHASE PHARMACEUTICALS I | $0 | – | -130,920 | -100.0% | -0.35% | – |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -88,724 | -100.0% | -0.48% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -76,713 | -100.0% | -0.49% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -256,431 | -100.0% | -0.52% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -90,551 | -100.0% | -0.57% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -7,590 | -100.0% | -0.81% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -58,867 | -100.0% | -1.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| REGENERON PHARMACEUTICALS | 31 | Q3 2023 | 1.8% |
| INCYTE CORP | 31 | Q3 2023 | 2.1% |
| ENANTA PHARMACEUTICALS INC | 31 | Q3 2023 | 2.2% |
| EXELIXIS INC | 31 | Q3 2023 | 1.8% |
| VANDA PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| IRONWOOD PHARMACEUTICALS INC | 31 | Q3 2023 | 2.0% |
| LIGAND PHARMACEUTICALS INC | 31 | Q3 2023 | 1.5% |
| GILEAD SCIENCES INC | 31 | Q3 2023 | 1.6% |
| HALOZYME THERAPEUTICS INC | 31 | Q3 2023 | 1.7% |
View Virtus ETF Advisers LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-15 |
| 13F-HR | 2023-11-07 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Virtus ETF Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.